Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023 [Yahoo! Finance]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Yahoo! Finance
Research and Development: R&D expenses dropped to $26.8 million in Q4, down from $46.2 million in Q4 2022. General and Administrative Expenses: G&A expenses were $17.2 million in Q4, a decrease from $22.4 million in the same period last year. Restructuring Savings: Anticipated annual cash savings of $75-$85 million starting in 2024. Cash Runway: Year-end cash balance expected to support operations into Q4 2024. Warning! GuruFocus has detected 8 Warning Signs with MCRB. On March 5, 2024, Seres Therapeutics Inc ( NASDAQ:MCRB ) released its 8-K filing , announcing the fourth quarter and full year financial results for 2023. The company, a pioneer in microbiome therapeutics, has made significant strides with the launch of its first commercial product, VOWST, for the prevention of recurrent Clostridioides difficile infection (CDI). Company Overview Seres Therapeutics Inc is a trailblazer in the field of microbiome therapeutics, operating primarily in the United States. The c
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTBusiness Wire
- Global Microbiome Manufacturing Industry Research 2024: A $187 Billion Market by 2035 with Close to 170 Trials Evaluating Microbiome Therapeutics to Treat Infectious Diseases and Oncological Disorders [Yahoo! Finance]Yahoo! Finance
- Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
MCRB
Earnings
- 11/2/23 - Beat
MCRB
Sec Filings
- 4/23/24 - Form 8-K
- 4/8/24 - Form 4
- 4/8/24 - Form 4
- MCRB's page on the SEC website